BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss

Reuters

Nov 18, 2025

<a href="https://laohu8.com/S/BICX">BioCorRx Inc.</a> reports Q3 revenue of $635,224 and reduced net loss

BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584953929"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584953929\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584953929?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584953929","market":"fut","top_or_hot":-1,"title":"BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BICX\">BioCorRx Inc.</a> reports Q3 revenue of $635,224 and reduced net loss\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BICX\">BioCorRx Inc.</a> reports Q3 revenue of $635,224 and reduced net loss\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BICX","symbol_name":"BioCorRx Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL9zk6n9:1","article_id":"2584953929","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584953929","pubTimestamp":1763475256,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BICX":"BioCorRx Inc.","BK4185":"保健护理机构"},"translate_title":"BioCorRx Inc.报告第三季度收入为635,224美元，净亏损减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BICX":0.9},"content_text":"BioCorRx Inc. reports Q3 revenue of $635,224 and reduced net loss\n    \n\n        BioCorRx Inc. reported revenue of $635.2 thousand for the third quarter of 2025, compared to $0 in the same period of 2024, primarily due to sales and distribution of LUCEMYRA through its subsidiary BioCorRx Pharmaceuticals Inc. Revenue for the nine months ended September 30, 2025, rose to $948.4 thousand from $7.7 thousand in the prior-year period. The company reduced its net loss to $808.5 thousand in Q3 2025 from $1.5 million in Q3 2024. During the quarter, BioCorRx continued integrating the LUCEMYRA acquisition and advanced development of BICX104 for opioid and alcohol use disorders. Management anticipates continued revenue consistency as commercial distribution expands.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCorRx Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}